- Molecular NameFluvastatin
- SynonymFluindostatin; Fluvastatin sodium; Fluvastatina [INN-Spanish]; Fluvastatine [INN-French]; Fluvastatinum [INN-Latin]
- Weight410.465
- Drugbank_IDDB01095
- ACS_NO93957-54-1
- Show 2D model
- LogP (experiment)4.17
- LogP (predicted, AB/LogP v2.0)3.98
- pka4.6
- LogD (pH=7, predicted)1.34
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-1.99
- LogSw (predicted, AB/LogsW2.0)0.01
- Sw (mg/ml) (predicted, ACD/Labs)0.02
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds8
- TPSA82.69
- StatusFDA approved
- AdministrationN/A
- PharmacologyA member of the drug class of statins, used to treat hypercholesterolemia and to prevent cardiovascular disease.
- Absorption_value100.0
- Absorption (description)Fluvastatin is rapidly and completely absorbed after oral administration
- Caco_2N/A
- Bioavailability24.0
- Protein binding99.0
- Volume of distribution (VD)0.35 to 0.42 L/kg
- Blood/Plasma Partitioning ratio (D_blood)Plasma:blood ratio is 1.8.
- MetabollsmUndergoes extensive first pass metabolism in the liver, the primary site of action. Hydroxylation of the indole rings at the 5- and 6- positions as well as N-dealkylation and β-oxidation of the side chains occurs. The main metabolite, N-desisopropylpropionic acid metabolite, is inactive. The active metabolite, fluvastatin lactone is rapidly eliminated and not in significant amounts in plasma.
- Half life0.5~1.0 h, also reported as 2.3 +/- 0.9 h.
- ExcretionExcretion is mainly via faeces, approx. 90% (< 2% unchanged drug) and 6% in urine. Fluvastatin is secreted in breast milk.
- Urinary ExcretionN/A
- Clerance36.6 L/h; body clearance, 0.97 L/h/kg
- ToxicityThere are no clinically significant adverse reactions with a 60 mg dose of fluvastatin sodium (the maximum dose used in healthy volunteers). Potential hazards to the fetus.
- LD50 (rat)N/A
- LD50 (mouse)N/A